Authors: C Roerholt P Eiken B Abrahamsen
Publish Date: 2008/06/13
Volume: 20, Issue: 2, Pages: 299-
Abstract
Initiation and compliance with antiosteoporotic therapy was assessed in 152777 fracture patients in a national populationbased cohort study Prescription rates were low especially following hip fracture Persistence has improved with almost 2/3 of patients who began raloxifene or weekly alendronate obtaining treatment durations equalling those of the licensing trialsWe used national registers to identify patients born 1945 or earlier who sustained a fracture 1997–2004 N = 152777 Initiation of antiosteoporotic therapy was defined as redemption of at least one prescription in the year following fracture Persistence was defined as duration of time maintaining a medication possession ratio 75Treatment initiation within 1 year was highest after spine fracture 396 of women began therapy in 2004 compared with 195 in 1997 In men 165 began therapy in 2004 vs 80 in 1997 Following hip fracture 92 of women and 41 of men began therapy in 2004 vs 34 and 07 in 1997 respectively Median persistence years was 28 for daily alendronate 38 for weekly alendronate 25 for etidronate and 47 for raloxifene The risk of discontinuing or changing therapy increased with agePrescription rates for antiosteoporotic medication are very low especially in hip fracture and in men Rates were 1/3 of those reported in the US Persistence has improved with almost 2/3 of patients who began raloxifene or weekly alendronate now obtaining treatment durations equalling those of the licensing trials
Keywords: